McKesson Medical-Surgical’s recently signed exclusive agreement with bioMerieux calls for McKesson Laboratory Solutions sales reps to offer the following bioMerieux products and reagents to community hospitals, that is, hospitals with less than 150 beds:
- VIDAS® B•R•A•H•M•S PCT™ run on VIDAS® 3 for guided antibiotic therapy in sepsis and lower respiratory-tract infections.
- BACT/ALERT® and FAN®Plus Media that optimizes time to detection and microorganism recovery.
- VITEK® 2 for same day microbial identification and antibiotic susceptibility testing results.
McKesson has existing lab relationships with community hospitals, but this is the company’s first agreement with bioMerieux.
“This reinforces McKesson’s commitment to bring a full suite of diagnostic solutions to community hospitals and support their efforts of effective antibiotic stewardship,” Doug Shaver, senior vice president and general manager, McKesson Laboratory Solutions, was quoted as saying.
McKesson has steadily accelerated its investment and growth in laboratory services over the past several years, the company pointed out in a press release. This includes the 2016 acquisition of LABSCO, a national distributor of laboratory equipment and supplies.